April 26, 2021 05:56 AM EDTUpdated April 27, 05:54 AM
Financing

Christoph West­phal and the crew at No­var­tis-backed TScan aren't wait­ing to take their pre­clin­i­cal TCR pitch to Nas­daq

John Carroll

Editor & Founder

Just 3 months ago, TScan CEO David South­well told End­points News’ Nicole De­Feud­is that it was like­ly the on­col­o­gy start­up would go pub­lic at some …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times